

Institute for Cannabis Therapeutics - Research Reference

Title	Author	Date	Source	Website /Contact	References/Citations
<u>MMJ & Addiction treatment</u>	Ronald Swartz	8-Mar-2010	Harm Reduction Journal		
<u>US IA: Edu: State Board Recommends Legalizing Medical Marijuana</u>	Jordan Fries	18-Feb-2010	The Daily Iowan	http://www.dailyiowan.com/	
<u>Gold Standard Studies Show That Inhaled Marijuana is Medically Safe and Effective</u>	Paul Armentano, NORML Deputy Director	18-Feb-2010	California Center for Medicinal Cannabis Research(CMCR)	http://blog.norml.org/2010/02/17/CEgold-standard1-studies-show-that-inhaled-marijuana-is-medically-safe-and-effective/	
<u>UC STUDIES FIND PROMISE IN MEDICAL MARIJUANA</u>	John Hoeffel	18-Feb-2010	Los Angeles Times (CA) Page AA3	Website: http://www.latimes.com/The-report http://www.cmcr.ucsd.edu/CMCR_REPORT_FEB17.pdf , Details: http://www.mapinc.org/media/219	Center for Medicinal Cannabis Research
<u>ACLU Applauds Rescheduling of Marijuana, dropping lawsuit</u>		17-Feb-2010	American Civil Liberties Union of Iowa	http://www.aclu-ia.org/	Randall Wilson, Legal director of the ACLU of Iowa.
<u>FDA APPROVES CANNABIS FOR PTSD VETERANS</u>		17-Feb-2010		http://www.news-medical.net/news/20100217/FDA-approved-cannabis-medicines-needed-for-veterans-to-relieve-symptoms-of-PTSD.aspx	Mitch Earleywine, Ph.D. Professor of Psychology at the State University of New York, Dr. Robert Melamede, Cannabis Science President and CEO

Institute for Cannabis Therapeutics - Research Reference

Title	Author	Date	Source	Website /Contact	References/Citations
<u>Marijuana Rescheduling (Background and Research)</u>	Brief prepared by Paige Clark, Pharmacist Consultant for Oregon Board of Pharmacy	19-Jan-2010	Oregon Board of Pharmacy 2010 January/Handout #2	OBOP Staff Research	See document's Item B - Summary Statements of Example Articles
<u>AMA Report Recognizes Medical Benefits of Marijuana, Urges Further Research</u>	Kris Hermes, Media Specialist, Americans for Safe Access	10-Nov-2009	PRESS RELEASE-Americans for Safe Access	http://www.SafeAccessNow.org	Executive Summary of AMA Report, http://AmericansForSafeAccess.org/downloads/AMA_Report_Executive_Summary.pdf , Recommendations of AMA Report http://AmericansForSafeAccess.org/downloads/AMA_Report_Recommendations.pdf , American College of Physicians resolution http://www.acponline.org/advocacy/where_we_stand/other_issues/medmarijuana.pdf
<u>AMA Urges Reclassifying Marijuana</u>					Dr. Sunil Aggrawal, ASA Medical and Scientific Advisory Board member
<u>Marijuana Dispensaries and the Federal Government: Recommendations to the Obama Administration 2009</u>	Andrea G. Barthwell, MD	2-Nov-2009	The Journal of Global Drug Policy and Practice	http://www.globaldrugpolicy.org/	see document's 21 references

Institute for Cannabis Therapeutics - Research Reference

Title	Author	Date	Source	Website /Contact	References/Citations
<u>Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions</u>	Sunil K. Aggarwal, PhD, Gregory T. Carter, MD, MS, Mark D. Sullivan, MD, PhD, Craig ZumBrunnen, PhD, Richard Morrill, PhD, Jonathan D. Mayer, PhD	May/June 2009	Journal of Opioid Management	University of Washington	See document's 105 references
<u>Cannabinoid Action Induces Autophagy-Mediated Cell Death Through Stimulation of ER Stress in Human Glioma Cells</u>	Salazar M, Carracedo A, Salanueva JJ.	2009;119(5):	J Clin Invest.	http://www.erowid.org/references/refs_view.php?ID=7487	See document's 377 references
<u>Cannabis Review</u>	Dr. Arno Hazecamp	2008-2009	Department of Plant Metabolomics, Leiden University, Leiden, the Netherlands		See document's 377 references
<u>Medical Marijuana and the Developing Role of the Pharmacist</u>	Matthew J. Seamon, Pharm.D., J.D., Jennifer A. Fass, Pharm. D., Maria Maniscalco-Feichti, Pharm.D., Nada A. Abu-Shraie, B.Sc. Pharm	15-May-2007	American Society of Health-System Pharmacists, Inc.	contact: Dr. Seamon, Nova Southeastern University, mseamon@nova.edu	See document's 70 references
<u>Effects of Marijuana Smoking on Pulmonary Function and Respiratory Complications: A Systematic Review</u>	Tetrault JM, Crothers K, Moore BA, et al.	2007;167(3):	Arch Intern Med.	http://www.erowid.org/references/refs_view.php?ID=7489	

Institute for Cannabis Therapeutics - Research Reference

Title	Author	Date	Source	Website /Contact	References/Citations
<u>Cannabinoids and cancer: pros and cons of an antitumour strategy</u>	Maurizio Bifulco, Chiara Laezza, Simona Pisanti, and Patrizia Gazzero	May-06	British Journal of Pharmacology, Università degli Studi di Salerno, Salerno, Italy and di Endocrinologia ed Oncologia Sperimentale I.E.O.S., CNR Napoli, Italy	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617062/?tool=pubmed	See document's reference pages
<u>Marijuana Use and the Risk of</u>	Hashibe M, Morgenstern H, Cui Y, et al.	2006;15(10):		http://www.erowid.org/references/refs_view.php?ID=6754	
<u>The Brain's own Marijuana</u>	Rober A. Nicoll and Bradley E. Alger	Dec 2004	Scientific American	www.sciam.com	Marijuana and Medicine. Edited by J.E. Joy, S.J. Watson, Jr., and J.A. Benson, Jr. Institute of Medicine, 1999, Endocannabinoid Signaling in the Brain. R.I. Wilson and R.A. Nicoll in Science, Vol. 296, pages 678-682; April 26, 2002. Retrograde Signaling in the Regulation of Synaptic Transmission: Focus on Endocannabinoids. B.E. Alger in Progress in Neurobiology, vol. 68, No. 4, pages 247-286: November 2002
<u>Pharmacological actions and therapeutic uses of cannabis and cannabinoids</u>	R.N. Kumar, Dr. W.A. Chambers and R.G. Pertwee	6-Jun-2001	University of Aberdeen, Aberdeen UK-Review Article	alastair.chambers@arh.gampian.scot.nhs.uk	See document's 79 references

Institute for Cannabis Therapeutics - Research Reference

Title	Author	Date	Source	Website /Contact	References/Citations
<u>Therapeutic aspects of cannabis and cannabinoids</u>	Philip Robson, FRCPsch	2001	British Journal of Psychiatry (2001)	Warneford Hospital, Oxford	See document's references page 114-115

Institute for Cannabis Therapeutics - Research Reference

Abstract/Content Info

Conclusions: This exploratory study suggests that medical marijuana is consistent with participation in other forms of drug treatment and may not adversely affect positive treatment outcomes.

STATE BOARD RECOMMENDS LEGALIZING MEDICAL MARIJUANA- Officials from the Iowa Board of Pharmacy voted unanimously to recommend that the state Legislature legalize the use of medical marijuana on Wednesday.

The results of a series of randomized, placebo-controlled clinical trials assessing the efficacy of inhaled marijuana consistently show that cannabis holds the state legislature by the California Center for Medicinal Cannabis Research findings of a 24-page report issued earlier today to the Californiatherapeutic value comparable to conventional medications, according to (CMCR).

Cannabis Can Greatly Ease Neuropathic Pain and Muscle Spasms, Researchers Show. With an innovative but little-known state program to study medical marijuana about to run out of money, researchers and political supporters said Wednesday the results show promise.

The ACLU Foundation of Iowa [ACLU of Iowa], announces today, that it will likely drop its lawsuit seeking rescheduling of marijuana by the Iowa Pharmacy Board in response to the board's decision today to voluntarily recommend that marijuana be moved from Schedule I to Schedule II of Iowa's controlled substances act.

Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

Abstract/Content Info

Houston, TX -- The American Medical Association (AMA) voted today to reverse its long-held position that marijuana be retained as a Schedule I substance with no medical value. The AMA adopted a report drafted by the AMA Council on Science and Public Health (CSAPH) entitled, "Use of Cannabis for Medicinal Purposes," which affirmed the therapeutic benefits of marijuana and called for further research.

The oldest national doctors' group has said cannabis should be classified as a medicine and called for more research into the drug's potential. The move by the American Medical Association, the largest organization of physicians with nearly 250,000 members, urges the federal government to reschedule marijuana to a level with other medicines and make it available for more cannabinoid drug development research and clinical trials.

Cannabis dispensaries are proliferating at a rapid rate - a cause for concern, given the potential for such operations to take advantage of desperate patients and put seriously ill patients at affirmative risk. Local jurisdictions do not have sufficient resources to deal with these abuses. Requiring the DEA unequivocally to take a hands-off approach, no matter how egregious the dispensary's practices, will not serve the best interests of patients.

Institute for Cannabis Therapeutics - Research Reference

Abstract/Content Info

Cannabis, (marijuana) has been used for medicinal purposes for millennia, said to be first noted by the Chinese in c. 2737 BCE. Medicinal cannabis arrived in the United States much later, burdened with a remarkably checkered, yet colorful, history. Despite early robust use, after the advent of opioids and aspirin, medical cannabis use faded. Cannabis was criminalized in the United States in 1937, against the advice of the American Medical Association submitted on record to Congress. The past few decades have seen renewed interest in medical cannabis, with the National Institute of Medicine, and the American College of Physicians, all issuing statements of support for further research and development. The recently discovered endocannabinoid system has greatly increased our understanding of the actions of exogenous cannabis. Endocannabinoids appear to control pain, muscle tone, mood state, appetite, and inflammation, among other effects. Cannabis contains more than 100 different cannabinoids and has the capacity for analgesia through neuromodulation in

1. An Introduction to the Cannabis Plant, 2. Cannabinoids, 3. Sites and Mechanisms of Action of Cannabinoids, 4. Biological effects of the Cannabinoids, 5. Non-Cannabinoid Constituents of Cannabis, 6. Cannabis as a Medicine, 7. Practical Aspects of Cannabis Research. 8. References

The pharmacology, therapeutic uses, safety, drug-drug interactions, and drug-disease interactions of medical marijuana are reviewed, and the legal issues related to its use and the implications of medical marijuana for the pharmacist are presented.

Institute for Cannabis Therapeutics - Research Reference

Abstract/Content Info

In the last two decades, research has dramatically increased the knowledge of cannabinoids biology and pharmacology. In mammals, compounds with properties similar to active components of Cannabis sativa, the so called endocannabinoids, have been shown to modulate key cell-signalling pathways involved in cancer cell growth, invasion and metastasis. To date, cannabinoids have been licensed for clinical use as palliative treatment of chemotherapy, but increased evidences showed direct antiproliferative actions of cannabinoid agonists on several tumour cells in vitro and in animal models. In this article, we will review the principal molecular pathways modulated by cannabinoids on cancer and summarize pros and cons evidence on the possible future use of endocannabinoid-based drugs in cancer therapy.

Cancer Epidemiol Biomarkers

Marijuana and related drugs affect behavior by acting on receptors for compounds called endocannabinoids that are produced by the brain. These endocannabinoids participate in regulating pain, anxiety, hunger and vomiting, among other processes. This wide range of effects explains why the use of marijuana seems to elicit so many different responses. By developing drugs that can mimic specific beneficial actions of endocannabinoids-without triggering some of the adverse effects of marijuana-researchers hope to find new treatments for diverse problems.

Summary This review highlights the pharmacology, pharmacokinetics, pharmacological actions, therapeutic uses and adverse effects of cannabinoids. The effect of cannabinoids on anaesthesia is mentioned briefly. Important advances have taken place in cannabinoid research over the last few years and have led to the discovery of novel ligands. The possible clinical applications of these ligands and the direction of future research are discussed.

Institute for Cannabis Therapeutics - Research Reference

Abstract/Content Info

Results and Conclusions Cannabis and some cannabinoids are effective anti-emetics and analgesics and reduce intra-ocular pressure. There is evidence of symptom relief and improved well-being in selected neurological conditions, AIDS and certain cancers. Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity requires clarification. Other properties identified by basic research await evaluation. Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe in overdose but often produces unwanted effects, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. The discovery of specific receptors and natural ligands may lead to drug developments. Research is needed to optimise dose and route of administration, quantify therapeutic and adverse effects, and examine interactions.